Exscientia Past Earnings Performance
Past criteria checks 0/6
Exscientia's earnings have been declining at an average annual rate of -44.5%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 4% per year.
Key information
-44.5%
Earnings growth rate
-19.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -4.0% |
| Return on equity | -43.8% |
| Net Margin | -616.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Exscientia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 21 | -130 | 43 | 111 |
| 31 Mar 24 | 20 | -129 | 38 | 119 |
| 31 Dec 23 | 20 | -146 | 45 | 128 |
| 30 Sep 23 | 24 | -144 | 42 | 135 |
| 30 Jun 23 | 22 | -148 | 41 | 139 |
| 31 Mar 23 | 26 | -141 | 42 | 139 |
| 31 Dec 22 | 27 | -119 | 38 | 129 |
| 30 Sep 22 | 25 | -100 | 35 | 112 |
| 30 Jun 22 | 36 | -69 | 34 | 88 |
| 31 Mar 22 | 29 | -59 | 29 | 63 |
| 31 Dec 21 | 27 | -49 | 26 | 44 |
| 30 Sep 21 | 27 | -36 | 21 | 29 |
| 30 Jun 21 | 10 | -39 | 14 | 19 |
| 31 Mar 21 | 13 | -24 | 8 | 13 |
| 31 Dec 20 | 10 | -22 | 6 | 11 |
| 31 Dec 19 | 9 | -6 | 5 | 7 |
Quality Earnings: 0RK is currently unprofitable.
Growing Profit Margin: 0RK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RK is unprofitable, and losses have increased over the past 5 years at a rate of 44.5% per year.
Accelerating Growth: Unable to compare 0RK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.6%).
Return on Equity
High ROE: 0RK has a negative Return on Equity (-43.78%), as it is currently unprofitable.